Lin S Y, Xia W, Wang J C, Kwong K Y, Spohn B, Wen Y, Pestell R G, Hung M C
Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6. doi: 10.1073/pnas.060025397.
Beta-catenin can function as an oncogene when it is translocated to the nucleus, binds to T cell factor or lymphoid enhancer factor family members, and transactivates its target genes. In this study, we demonstrate that cyclin D1 is one of the targets of beta-catenin in breast cancer cells. Transactivation of beta-catenin correlated significantly with cyclin D1 expression both in eight breast cell lines in vitro and in 123 patient samples. More importantly, we found that high beta-catenin activity significantly correlated with poor prognosis of the patients and was a strong and independent prognostic factor in breast cancer. Our studies, therefore, indicated that beta-catenin can be involved in breast cancer formation and/or progression and may serve as a target for breast cancer therapy.
当β-连环蛋白转位至细胞核，与T细胞因子或淋巴样增强因子家族成员结合并反式激活其靶基因时，它可发挥癌基因的作用。在本研究中，我们证明细胞周期蛋白D1是乳腺癌细胞中β-连环蛋白的靶标之一。在体外的8种乳腺癌细胞系以及123例患者样本中，β-连环蛋白的反式激活均与细胞周期蛋白D1的表达显著相关。更重要的是，我们发现β-连环蛋白的高活性与患者的不良预后显著相关，并且是乳腺癌中一个强大且独立的预后因素。因此，我们的研究表明β-连环蛋白可能参与乳腺癌的形成和/或进展，并且可能成为乳腺癌治疗的一个靶点。
